HeartWare International Inc  

(Public, NASDAQ:HTWR)   Watch this stock  
Find more results for htwr
+1.81 (3.34%)
After Hours: 56.57 +0.63 (1.12%)
Oct 5, 4:10PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 55.20 - 57.85
52 week 50.03 - 95.59
Open 55.20
Vol / Avg. 914,813.00/582,092.00
Mkt cap 936.47M
P/E     -
Div/yield     -
EPS -2.92
Shares 17.30M
Beta 0.38
Inst. own 115%
Nov 9, 2015
HeartWare International Inc at Credit Suisse Healthcare Conference Add to calendar
Oct 28, 2015
Q3 2015 HeartWare International Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 9, 2015
HeartWare International Inc at Wells Fargo Healthcare Conference - Webcast
Sep 1, 2015
Heartware International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. - Webcast
Aug 13, 2015
HeartWare International Inc at Canaccord Genuity Growth Conference
Jul 30, 2015
Q2 2015 HeartWare International Inc Earnings Release
Jul 30, 2015
Q2 2015 HeartWare International Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -37.23% -6.96%
Operating margin -33.22% -0.04%
EBITD margin - -5.37%
Return on average assets -24.30% -4.54%
Return on average equity -53.89% -9.51%
Employees 585 -
CDP Score - -


500 Old Connecticut Path
United States - Map
+1-508-7390873 (Phone)
+1-508-7390948 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Heartware International, Inc. is a medical device company. The Company develops and manufactures miniaturized implantable heart pumps or ventricular assist devices for patients suffering from advanced heart failure. The HeartWare Ventricular Assist System (HVAD System), which includes a ventricular assist device (VAD) or blood pump, patient accessories and surgical tools, provides circulatory support for patients in the advanced stage of heart failure. The core of the HVAD System is a continuous flow blood pump, the HVAD pump. The HVAD System is designed to be implanted adjacent to the heart, avoiding abdominal surgery, directly adjacent to the heart. The Company's hybrid system is used for suspending the impeller. The impeller is suspended within the pump housing by the opposing forces of passive magnets and hydrodynamic thrust generated by the pump impeller, which circulates a cushion of blood.

Officers and directors

C. Raymond Larkin Jr. Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Douglas Evan Godshall M.B.A. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Seth L. Harrison M.D. Deputy Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Peter F. McAree Chief Financial Officer, Senior Vice President, Treasurer
Age: 50
Bio & Compensation  - Reuters
Jeffrey A. LaRose Executive Vice President, Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
Lawrence Knopf Senior Vice President, General Counsel, Secretary
Age: 53
Bio & Compensation  - Reuters
James Schuermann Senior Vice President - Sales and Marketing
Age: 46
Bio & Compensation  - Reuters
Mark Strong Senior Vice President, Research and Development and Quality Assurance
Age: 43
Bio & Compensation  - Reuters
Robert Yocher Senior Vice President, Regulatory Affairs
Age: 63
Bio & Compensation  - Reuters
Katrin Leadley M.D. Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters